It is usually difficult to turn around when taking entecavir for major triple positive. Entecavir belongs to a class of antiviral drugs, in the form of a nucleotide analog, which can be used to inhibit the replication of the hepatitis B virus, although it cannot completely remove the hepatitis B virus from the body. Therefore, the goal of the current treatment of hepatitis B is not to remove the hepatitis B virus, but to inhibit its replication. Hepatitis B surface antigen, e antigen, and core antibody positivity are classified as hepatitis B triple positive. Patients with chronic hepatitis B have a lower chance of converting to surface antigen, and patients with hepatitis B triple positive can take entecavir to inhibit viral replication and increase the chance of converting to surface antigen, but overall it is generally difficult to convert to surface antigen. Common adverse effects of entecavir include headache, dizziness, nausea, and fatigue, etc. It is contraindicated for those who are allergic to entecavir, and is contraindicated for breastfeeding and pregnant women. In addition, the use of entecavir carries certain risks and patients need to be supervised by a specialist.